Sign In
Buy TRVI
$13.45
-0.0500 (-0.370%)
At Close: Jun 03, 2026
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know
10:56am, Friday, 11'th Jul 2025
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 231.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
07:30am, Tuesday, 01'st Jul 2025
NEW HAVEN, Conn. , July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
PHILADELPHIA, June 26, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Trevi Therapeutics, Inc. (NASDAQ: TRVI) (“Trevi”) on behalf of the company's long-term investors.
Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC acquired a new stake in shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities
NEW HAVEN, Conn. , June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
10:15pm, Tuesday, 03'rd Jun 2025
NEW HAVEN, Conn. , June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphin
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
04:01pm, Monday, 02'nd Jun 2025
NEW HAVEN, Conn. , June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine E
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
01:42pm, Monday, 02'nd Jun 2025
Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming June Conferences
07:30am, Thursday, 29'th May 2025
NEW HAVEN, Conn. , May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
07:00am, Tuesday, 20'th May 2025
Results of analyses presented at an investor meeting during the American Thoracic Society 2025 International Conference NEW HAVEN, Conn. , May 20, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasda
Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High?
11:00am, Wednesday, 14'th May 2025
The mean of analysts' price targets for Trevi Therapeutics (TRVI) points to a 195.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement am
Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
04:16am, Sunday, 11'th May 2025
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Ch
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
04:05pm, Thursday, 08'th May 2025
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positiv
